Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

A DAILY weight loss pill that works like Ozempic can help users shed an average of almost two stone,  a study reveals. People ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Trump told CNBC he will initially impose a “small tariff” on pharmas in the next week or so, but will raise it to 150% in a ...

Biographer Peter Guralnick shows us that loving Elvis also means loving Colonel Parker, no matter how grudgingly.